CCR2 and neoplasm: Following i.t. DMXAA, both control and CCR2 KO mice showed reduction in UPS tumor volumes (Figures 7E), tumor bioluminescence (Figure 7F), and tumor free survival 90-days post-UPS engraftment (Figure 7G).